Initiator Pharma Wins European Patents for Female Sexual Dysfunction Treatment Use, Formulation

03:59 AM EDT, 08/19/2026 (MT Newswires) -- Initiator Pharma (INIT.ST) secured patents related to its female sexual dysfunction treatment, pudafensine, from the European Patent Office. The Danish clinical-stage pharmaceutical company said Wednesday that the two patents cover the therapy's use for pain alleviation and its oral formulation. The company noted that the pain treatment patent will be valid until 2043, while the formulation patent will be active until 2044.